Ahmadi-Beni Reza, Najafi Ali, Savar Seyed Mehrdad, Mohebbi Niayesh, Khoshnevisan Alireza
Department of Medical Genetics, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Neurol. 2019 Jul 6;18(3):127-133.
Glioblastoma multiforme (GBM), the most frequent malignant and aggressive primary brain tumor, is characterized by genetically unstable heterogeneous cells, diffused growth pattern, microvascular proliferation, and resistance to chemotherapy. Extensive investigations are being carried out to identify the molecular origin of resistance to chemo- and radio-therapy in GBM and find novel targets for therapy to improve overall survival rate. Dimethyl fumarate (DMF) has been shown to be a safe drug with limited short and long-term side effects, and fumaric acid esters (FAEs), including DMF, present both anti-oxidative and anti-inflammatory activity in different cell types and tissues. DMF has also anti-tumoral and neuroprotective effects and so it could be repurposed in the treatment of this invasive tumor in the future. Here, we have reviewed DMF pharmacokinetics and different mechanisms by which DMF could have therapeutic effects on GBM.
多形性胶质母细胞瘤（GBM）是最常见的恶性侵袭性原发性脑肿瘤，其特征是具有基因不稳定的异质性细胞、弥漫性生长模式、微血管增殖以及对化疗的抗性。目前正在进行广泛的研究，以确定GBM中对化疗和放疗产生抗性的分子起源，并寻找新的治疗靶点，以提高总体生存率。已证明富马酸二甲酯（DMF）是一种安全的药物，其短期和长期副作用有限，并且包括DMF在内的富马酸酯（FAE）在不同细胞类型和组织中均具有抗氧化和抗炎活性。DMF还具有抗肿瘤和神经保护作用，因此将来它可能被重新用于治疗这种侵袭性肿瘤。在此，我们综述了DMF的药代动力学以及DMF对GBM产生治疗作用的不同机制。
